YTHDF2 facilitates cyclin-dependent kinase inhibitor 1B (CDKN1B) mRNA degradation and plays a cisplatin-desensitizing role in intrahepatic cholangiocarcinoma (ICC) [264]. Here, CDKN1B is linked to intrahepatic cholangiocarcinoma.